Impact of Helminth Infections During Pregnancy on Humoral Vaccine Immunogenicity in Infants
NCT ID: NCT02714348
Last Updated: 2016-03-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
323 participants
OBSERVATIONAL
2014-02-28
2016-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Since most vaccines are given shortly after birth, an effect of parasites on infant immunogenicity is of particular concern. Therefore, within this study the investigators aim to investigate if maternal infection influences vaccine immunogenicity in the newborn.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Trial Investigating the Influence of BCG and Hepatitis B Immunisation at Birth on Neonatal Immune Responses: The Early Life Vaccines and Immunity Study
NCT02444611
Immunology of Non-specific Effects of Vaccine
NCT00168545
Should Low Birth Weight Infants Be Vaccinated With BCG Vaccine at Birth in Developing Countries?
NCT00146302
The Interaction Between Measles and DTP Vaccination
NCT02710045
Long-term Follow-up of Measles Antibodies
NCT00168571
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Effect of helminth infection on vaccine immunogenicity
Observational; immunology
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Willingness to deliver in one of the two maternities in the study area
* Willingness and ability to comply with study protocol for the duration of the trial
* Willingness to give blood for the examinations and to provide samples for helminth assessment (stool, urine, blood)
Exclusion Criteria
* Withdrawal of consent
* Poor general health (including a hemoglobin level out of local reference range)
* Signs of symptoms of helminth infection which needs immediate treatment of the mother
* Planned migration from the area
18 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital Tuebingen
OTHER
Centre de Recherche Médicale de Lambaréné
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Meral Esen
Groupleader immunology and clinical trials
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Akim A Adegnika, Md, PhD
Role: STUDY_DIRECTOR
Centre de Recherche Médicale de Lambaréné
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HelmVacc_II
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.